JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter and the full year ended December 31, 2006. Net sales for the fourth quarter of 2006 increased 63% to $2,277 million, compared to $1,401 million in the fourth quarter of 2005. The main contributors to the growth in sales for the quarter were the inclusion of Ivax sales, which benefited all regions, and new products sold in the U.S. that were not sold in the comparable quarter of 2005. Net sales for fiscal 2006 reached $8.4 billion, an increase of 60% over 2005 sales.
